Articles

MedAxiom ASNC Nuclear Imaging

A new survey reveals that cardiologists around the United States are seeing more patients than ever before, yet performing fewer advanced nuclear tests on those patients on average. The survey...

August 27, 2012 — Positron Corp., a molecular imaging healthcare company, announced the submission of a drug master file (DMF) with the U.S. Food and Drug Administration (FDA) for the production...

Single photon emission computed tomography (SPECT) remains a well-entrenched imaging modality for nuclear myocardial perfusion imaging (MPI) more than 30 years after its introduction....

April 27, 2012 - More than 150 molecular imaging professionals gathered last week at the Society of Nuclear Medicine’s third Multimodality Cardiovascular Molecular Imaging Symposium held at the...

April 9, 2012 — After witnessing a downtrend for several years, revenues in the U.S. nuclear medicine and positron emission tomography (PET) imaging systems market finally pivoted in 2010. New...

Addressing concerns over radiation from cardiac imaging and procedures, the American College of Cardiology Foundation (ACCF), Duke University Clinical Research Institute (DCRI) and American Heart...

There are currently three major trends in cardiac nuclear perfusion imaging technology: advances in detector hardware, improved software and new radiotracers. These advances have enhanced the...

The new imaging modality of positron emission tomography (PET)/magnetic resonance imaging (MRI) was introduced to the U.S. market in June. The Siemens Biograph mMR (molecular MR) gained U.S. Food...

The U.S. Food and Drug Administration (FDA) is alerting healthcare professionals to stop using CardioGen-82 for cardiac positron emission tomography (PET) scans. The manufacturer, Bracco...

June 10, 2011 – The U.S. Food and Drug Administration (FDA) granted Siemens Healthcare 510(k) clearance for the Biograph mMR, the first system worldwide to enable simultaneous whole-body acquisition...